---
cssclasses: 
share_link: https://share.note.sx/c17pkijq#WQoghIsUlMNVEJfRFEB99oLkzW8wIQ1uckW6hRjZL5c
share_updated: 2024-06-18T19:02:33+08:00
notetoolbar: Study
---

> [!scroller] Table of Contents
> ```table-of-contents
> ```

# Regulation of Blood Glucose Level


|                                                         |                                                                                                                                                                            |
| ------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Insulin</mark><br><br>pb **B cells**  | Only hormone that **decreases glucose** level<br><br>Notes<br>- produced as **proinsulin** (not insulin immediately)<br>- **C-peptide** as byproduct of insulin production |
| <mark class="red">Glucagon</mark><br><br>pb **A cells** | **Main hyperglycemic** hormone                                                                                                                                             |
| Other **hyperglycemic** hormones                        | **Thyroxine**, **Cortisol**, **Growth hormone**, **Epinephrine**                                                                                                           |

# Diabetes Mellitus

- Metabolic disease characterized by **hyperglycemia** resulting from **defects in insulin ==secretion==, insulin ==action== or both.**

|                     |                                                                                                                                                                                                                                    |
| ------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| SYMPTOMS            | - Poly**uria**<br>- Poly**dipsia**<br>- Poly**phagia**<br>- **Blurred vision**<br>- **Pruritus**<br>- **Increased susceptibility to infection**<br>- **Hyperventilation**<br>- **Mental confusion**<br>- **Loss of consciousness** |
| LABORATORY FINDINGS | - ↑ **glucose** in plasma and urine<br>- ↑ urine **specific gravity**<br>- ↑ serum and urine **osmolality**<br>- **Ketones** in serum and urine<br>- ↓ blood and urine **pH**<br>- **Electrolyte** imbalance                       |


| Points of Difference              | <mark class="red">TYPE 1</mark>                                                                                                                                                                                                                                                                                                                                      | <mark class="red">TYPE 2</mark>                                                                                                                           |
| --------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Pathogenesis                      | Destruction of **pancreatic beta cells**, ==usually autoimmune column==<br><br>Absence of autoantibodies does not mean absence of Type 1!!!<br>- **Islet cell Abs (ICA)**<br>- **Insulin autoAbs (IAA)**<br>- **Abs to glutamic acid decarboxylase (GAD)**<br>- **Insulinoma-associated protein (IA2, ICA512)**<br><br>Strong association (**HLA DR** & **DQ loci**) | **Insulin resistance** and **progressive insulin deficiency**, <br>- ==no autoimmunity==                                                                  |
| Age of Onset                      | **Any**, but **most common in ==children== and young ==adults==**                                                                                                                                                                                                                                                                                                    | **More common with ==advancing age==**, but can occur in **children** and **adolescents**                                                                 |
| Risk Factors                      | - **Genetic**, <br>- **autoimmune**, <br>- **environmental**                                                                                                                                                                                                                                                                                                         | - **Genetic**, <br>- **obesity**, <br>- **sedentary** lifestyle, <br>- **race/ethnicity**, <br>- **hypertension**, <br>- **dyslipidemia**, <br>- **PCOS** |
| Prediabetes                       | Autoantibodies may be **present**                                                                                                                                                                                                                                                                                                                                    | Autoantibodies **absent**                                                                                                                                 |
| Medication/Therapy                | Insulin **absolutely necessary**; <br>**multiple daily injections** or **insulin pump**                                                                                                                                                                                                                                                                              | **Oral hypoglycemic agents**<br>Insulin **commonly needed**                                                                                               |
| Therapy to prevent or delay onset | **None**; ==clinical trials in progress==                                                                                                                                                                                                                                                                                                                            | **Lifestyle**<br>**Oral medications** #table-column                                                                                                       |

^2co833

## DIAGNOSIS OF DIBETES MELLITUS

| Tests                                                                                                                                                                                                               | NORMAL            | PREDIABETES         | PROVISIONAL DIAGNOSIS |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- | ------------------- | --------------------- |
| **<mark class="red">Random Plasma Glucose</mark>**<br>- must be accompanied w/ SS (polyphagiadipsia, uria)                                                                                                          | **<200** mg/dL    |                     | **≥ 200** mg/dL       |
| **<mark class="red">Fasting Plasma Glucose</mark>**<br>- ==preferred test==                                                                                                                                         | **70 - 99** mg/dL | **100 - 125** mg/dL | **≥ 126** mg/dL       |
| **<mark class="red">2-hr Plasma Glucose (OGTT)</mark>**<br>- not recommended, for clinical use<br>- required to collect 3 spx<br>- **diagnostic test for ==GDM==** (fasting & 2nd hour, include 1st hr only if GDM) | **< 140** mg/dL   | **140 - 199** mg/dL | **≥ 200** mg/dL       |
| **<mark class="red">HbA1c</mark>**<br>- used for ==long term monitoring==<br>- **2-3 months** glucose picture                                                                                                       | **< 5.7%**        | **5.7 - 6.4%**      | **≥ 6.5%**            |

^o1agxr

> [!NOTE]
> in the **absence of unequivocal hyperglycemia**, these criteria should be **confirmed by repeat testing on a ==different day==**

|                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">HbA1c</mark> <br>Glycosylated/Glycated                              | - Measure of glucose control over the **previous 2 to 3 months** (life span of a red cell)<br>- Any condition associated with shortened RBC survival or lower mean RBC age such as **==hemolysis==, ==recovery from acute blood loss==, ==transfusions== or ==splenectomy== lower the HbA1c level** because of reduced exposure to plasma glucose (contraindicated to ppl w/ ↓ RBC lifespan)<br>- Specimen: **EDTA whole blood**<br><br><6% = optimal<br>10% = fair<br>13-20% = poor control<br><br>**Goal of Therapy = ==7%== (tested 2x/year)**<br><br>reported together w/ estimated average blood glucose (eAG)<br>eAG (mg/dL) = (28.7 x HbA1C) - 46.7)<br><br>For every 1% ↑ HbA1C = 35mg/dL eAG |
| <mark class="red">Microalbuminuria</mark><br><br>monitor kidney function of ppl w/ DM | - Microalbumin measurements are useful to **assist in diagnosis** at an **early stage** and **BEFORE the development of PROTEINURIA.**<br>- An **annual assessment** of kidney function by the determination of urinary albumin excretion is recommended for **diabetic patients**<br><br>Characteristic findings: <br>30 - 300 mg of albumin/24 hours<br>20 - 200 ug/min (AER)<br>30 - 300 ug/mg creatinine on 2 to 3 collections (AC ratio)                                                                                                                                                                                                                                                         |
| <mark class="red">Ketones</mark>                                                      | compliance to therapy or medication<br>poorly controlled DM = ↑ Ketones                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Complications of Diabetes

|                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| --------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Acute</mark> Complications <br>(sudden)                   | <mark class="red">Diabetic ketoacidosis</mark> - occurs in Type 1 DM<br>- **HCO3** (15 mEq/L)<br>- **pH**  (<7.30)<br>- **glucose** (>= 200mg/dL)<br>- **anion gap** (↑)<br>- **ketones**  (↑)<br><mark class="red">Hyperglycemic hyperosmolar nonketotic coma</mark><br>- **Blood osmolarity** (>300 mOsm/L)<br>- **Glucose** (>1000 mg/dL)<br>- **Bicarbonate** and **ketones** (normal)<br>- **Lactic acid** (↑)<br><mark class="red">Insulin overdose hypoglycemia</mark><br>- **C-peptide** (undetectable/ ↓)<br><br>INSULINOMA vs INSULIN OVERDOSE (Hypoglycemia)<br>- C-peptide (↓ in insulin overdose)<br>- Insulinoma (↑ C - peptide)<br>(REMEMBER: C-peptide is a  byproduct of insulin production, Insulinoma produces insulin = ↑ C-peptide byproducts) |
| <mark class="red">Long-term</mark> Complications <br>(gradual, progressive) | - **Retinopathy** (50% px after 10 years)<br>- **Nephropathy** (Renal dss, proteinuria, ↑BUN, ↑creatinine)<br>- **Neuropathy** (Poor sensation, ulceration of skin - amputation)<br>- **Accelerated macrovascular disease** (coronary artery disease, cerebral vascular accident)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |


> [!NOTE] # Specimen Collection and Handling
> - Preferred specimen is drawn **early in the morning** after an **8-hour fast**
> - **Plasma** or **serum** can be used, but **preferred is ==venous plasma==**
> - ~ If not drawn in gray top tubes, specimen must be **separated from cells within 1 hour**
> - ? When blood specimen is left in **unseparated test tube**, glycolysis will reduce glucose by **5 to 10 mg/dl per hour**. This can be arrested by NaF.
> - Uncalibrated whole blood glucose usually runs **10 to 15% lower** than plasma glucose
> - After a **glucose load**, capillary values will increase by approximately **20 mg/dl**
> 

## Methods of Testing

|                                                 |                                                                                                                                                                                                                                                                                                                                   |
| ----------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Glucose oxidase</mark> method | - glucose oxidase enzyme - **Most Specific ENZYME** for glucose (wont react with other sugars)<br>- vulnerable to presence of reducing subs. (NOTE: if method uses peroxide, VULNERABLE to reducing subs.) = why glucose oxidase is not the reference<br>- falsely ↓ result = uric acid & ascorbic acid (are reducing substances) |
| <mark class="red">Hexokinase</mark> method      | - reference method<br>- false ↓ results = hemolysis & bilirubin<br>- NOT SPECIFIC enzyme<br>- **Most Specific METHOD**                                                                                                                                                                                                            |


> [!NOTE] 
> Most specific enzyme? glucose oxidase
> Most specific method? hexokinase method
> Responsible for specificity of hexokinase? G6PD

# Significant Plasma Proteins

|                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| -------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Prealbumin</mark>                                                                | - also known as **transthyretin**<br>- binds **retinol** and **thyroxine**<br>- sensitive marker of **poor nutritional status** (half life = 2 days)<br><br>- levels (CSF > plasma)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <mark class="red">Albumin</mark><br><br>- most anodal<br>- protein w/ highest dye binding capacity | - **most abundant** protein in the blood<br>- major contributor to **oncotic pressure**<br>- assessment of **nutritional status** (half life = 17 - 21 days (15-19 days), if albumin already present, malnutrition is present longer already)<br>- diabetes picture (only 4 weeks)<br>- Fructosamine assay (performed usually in px w/ hemolytic anemia)                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <mark class="red">a1 antitrypsin</mark>                                                            | - neutralizes **trypsin** and **elastase** (trypsin, elastase kills the infection agents, TOO MUCH result to normal cell destruction)<br>- deficiency results to: **Pulmonary Emphysema** & **Juvenile cirrhosis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <mark class="red">a1 acid glycoprotein</mark>                                                      | - also known as **orosomucoid**<br>- transports **progesterone** (binds progesterone, inactivates progesterone)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <mark class="red">a1 fetoprotein</mark>                                                            | - **Oncofetal antigen**; **principal fetal protein** (during 2nd trimester of pregnancy)<br>- marker for **hepatocellular carcinoma**<br><br>- measured in amniotic fluid/maternal serum or plasma (↓ AFP = Trisomy 21, ↑ AFP = Neutral tube defects)<br>- Tumor marker (hepatocellular carcinoma, testicular cancer)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <mark class="red">Haptoglobin</mark><br><br>a2 globulins                                           | - binds **free hemoglobin** (to converve the iron)<br>- decreases in **intravascular hemolysis**<br>- if hapto depleted = Hemoglobinuria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <mark class="red">Ceruloplasmin</mark><br><br>a2 globulins                                         | - protein with **enzymatic activity**, transports **copper**<br>- deficiency results to: <br>- Wilson's dss (↓ production Cerulo)<br>- Menke's dss (↓ absorption)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <mark class="red">a2 macroglobulin</mark><br><br>a2 globulins                                      | - **largest non-immunoglobulin** protein<br>- retained in **nephrotic syndrome**<br>- nephrotic syndrome (10x ↓ in production) - to main oncotic pressure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <mark class="red">Transferrin</mark><br><br>beta                                                   | - also known as **siderophilin**<br>- transports **iron**<br>- + **Albumin**, **Prealbumin**, **Transferrin** (NEGATIVE APRs)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <mark class="red">Hemopexin</mark><br><br>beta                                                     | - binds **heme**<br>- decreased in **intravascular** and **extravascular** hemolysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <mark class="red">Complement</mark><br><br>beta                                                    | - essential role in **immune response**<br>- **C3** = most abundant<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <mark class="red">Fibrinogen</mark><br><br>beta                                                    | - precursor of **fibrin clot**<br>- present in **plasma** but not in serum<br>- band in BETA region                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <mark class="red">C-reactive protein</mark><br><br>beta                                            | - **major acute-phase reactant**<br>- functions as an **opsonin**<br>- associated with **increased risk for CAD**<br>- sensitive but NONSPECIFIC marker (1000x, 4 hrs)<br><br>NOTES<br>- <mark class="red">Normal: <0.2 - 0.3 mg/dL (<2-3 mg/L)</mark><br>- <mark class="red">High level CRP elevation</mark> (> 1mg/dL or >10 mg/L) = assoc. w/ active inflammation, infection, collagen vascular dss<br>- <mark class="red">Low level CRP elevation</mark> (0.3 - 1 mg/dL or 3-10 mg/L) = indicative of cellular stress, assoc. w/ poor outcome following cardiovascular events, ↑ mortality<br><br><mark class="red">hsCRP</mark> = capable of detecting as low as 0.05 mg/dL or <0.5 mg/L)<br>- **<1mg/L** = low risk CVD<br>- **1 - 3 mg/L** = moderate risk CVD<br>- **> 3 mg/L** = high risk CVD |
| <mark class="red">Immunoglobulin</mark><br><br>gamma                                               | - antibodies; produced by **plasma cells**<br>- protection against foreign antigens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |



# Protein Determination Methods

|                                                               |                                                                                                                                                                                                                                                           |
| ------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">BIURET</mark> METHOD                        | - **Routine** method; requires **at least two peptide bonds** and an **alkaline medium**<br>- Based on the reaction of peptide bonds and cuprous ions forming a **violet complex** measured at **540nm**                                                  |
| <mark class="red">KJELDAHL</mark> METHOD                      | - **Classic** method, **reference** method<br>- Involves **digestion of protein** and measurement of its **nitrogen content**                                                                                                                             |
| <mark class="red">DIRECT OPTICAL</mark> METHOD<br>(UV method) | - Based on the **absorbance of proteins** at **UV spectrum**<br>- **<mark class="red">210 nm</mark>**: abs. due to **PEPTIDE BONDS**<br>- **<mark class="red">280 nm</mark>**: abs. due to AMINO ACIDS (**TRYPTOPHAN**)                                   |
| <mark class="red">DYE-BINDING TECHNIQUES</mark>               | - Mainly used for **albumin determination**; it binds to the dye causing a shift in the absorption maximum<br>- **<mark class="red">Bromcresol green</mark>** = common<br>- **<mark class="red">Bromcresol purple</mark>** = sensitive, specific, precise |



# Serum Protein Electrophoresis



|                                      |                                                                                                                                                                                                    |
| ------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| ![[Pasted image 20240423154939.png]] | <mark class="red">Reference Pattern</mark>                                                                                                                                                         |
| ![[Pasted image 20240423154950.png]] | <mark class="red">Acute Inflammation</mark> (Immediate response)<br><br>vs Chronic inflammation (↑ gamma region)                                                                                   |
| ![[Pasted image 20240423154959.png]] | <mark class="red">a1 Antitrypsin deficiency</mark><br><br>a1 flat curve<br><br>- Pulmonary emphysema<br>- Juvenile cirrhosis                                                                       |
| ![[Pasted image 20240423155011.png]] | <mark class="red">Hepatic cirrhosis</mark><br><br>b-gamma bridging<br><br>↑ production of a fast migrating immunoglobulin                                                                          |
| ![[Pasted image 20240423155022.png]] | <mark class="red">Nephrotic syndrome</mark><br><br>a2 spike<br><br>↑ a2 + B region<br>retention of A2 macroglobulin & hemopexin                                                                    |
| ![[Pasted image 20240423155033.png]] | <mark class="red">Monoclonal gammopathy</mark> <br><br>Gamma spike<br><br>- Multiple myeloma<br>- Waldenstrom macroglobulinemia<br>- Malignancies<br><br>Follow-up: Immunofixation electrophoresis |



|                                                                     |                                                                                                                                                                                               |
| ------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Inadvertent use of <mark class="red">plasma</mark> instead of serum | - Narrow distinct band in the **beta region** due to presence of fibrinogen                                                                                                                   |
| <mark class="red">Hemolysis</mark>                                  | - **Blip** in the pattern in the **late alpha 2** or **early beta region** due to presence of free hemoglobin<br>- A small blip in the alpha 2 region due to hemoglobin-haptoglobin complexes |


|                                                                                                                                                                                                                                                                                                                                                                          |                                      |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------ |
| <mark class="red">CSF</mark> ELECTROPHORESIS<br><br>CSF electrophoresis & serum electrophoresis (ordered together for comparison)<br><br>1: **NORMAL**<br>2: Oligoclonal bands in the **CSF only** (MS, Guillain-Barre syndrome, Malignancies, Neurosyphilis, Encephalitis)<br>3: Oligoclonal bands in the **CSF** & **serum** (Systematic, weakened BBB, HIV infection) | ![[Pasted image 20240423155208.png]] |
| <mark class="red">URINE</mark> ELECTROPHORESIS<br><br>1: **Normal**<br>2a: strong albumin, a1, B (**Glomerular proteinuria**)<br>2b: strong a1, a2, b; weak albumin (**Tubular proteinuria**)<br>2c: monoclonal light chains, BJP (**Overflow proteinuria**(Hemoglobinuria, Myoglobinuria))                                                                              | ![[Pasted image 20240423155223.png]] |


# LIPIDS AND LIPOPROTEINS

## MAJOR LIPOPROTEINS


|                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                       |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------- |
| - **Largest** and **least dense**<br>- Transport <mark class="red">EXOgenous</mark> TAG<br>- Apoproteins: <mark class="red">**B48**, **A2**, **CII**, **E**</mark><br><br>- NONmigrating<br>- responsible for **POSTPRANDIAL lipemia**<br><br>NOTES<br><mark class="red">Apoproteins</mark> - serve as markers for apoproteins<br>Lipoprotein **Density**  - **protein** content,<br>Lipoprotein **Size** - **lipid** content<br><br> | <mark class="red">CM</mark><br><br>transporter of TRIGLYCERIDES                       |
| - **Pre-B** lipoprotein<br>- Transports <mark class="red">ENDOgenous</mark> TAG<br>- Apoproteins: <mark class="red">**B100**, **C**, **E**</mark><br>                                                                                                                                                                                                                                                                                 | <mark class="red">VLDL</mark><br><br>transporter of TRIGLYCERIDES                     |
| - **Beta** lipoprotein<br>- Transports and deposits **cholesterol to peripheral cells** (chole should be sent to liver for processing!)<br>- Plasma level is directly proportional to risk of **atherosclerosis** and **CHD**<br>- Apoproteins: <mark class="red">**B100**</mark>                                                                                                                                                     | <mark class="red">LDL</mark><br><br>Bad Cholesterol<br><br>transporter of CHOLESTEROL |
| - **Smallest** and most dense<br>- **Alpha** lipoprotein<br>- **INVERSELY proportional to the risk of CVD**<br>- **REVERSE cholesterol** transport<br>- Apoproteins: <mark class="red">**A1**, **C**, **E**</mark>                                                                                                                                                                                                                    | <mark class="red">HDL</mark><br><br>transporter of CHOLESTEROL                        |

# Lipoprotein Classification

|                                                                                          |                                      |
| ---------------------------------------------------------------------------------------- | ------------------------------------ |
| <mark class="red">Ultracentrifugation</mark><br><br>- reference method for fractionation | ![[Pasted image 20240423155558.png]] |
| <mark class="red">Electrophoresis</mark>                                                 | ![[Pasted image 20240423155606.png]] |

# Measurement of Lipids and Lipoproteins



|                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| ------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">TOTAL CHOLESTEROL</mark> | ![[Pasted image 20240423165524.png]]<br><br>Measurements:<br>- **O2 consumption**<br>- **Spectrophotometric (==cholest-4-en-3-one== or ==reduced chromogen==)**<br><br>Interferences: <br>- **Reducing substances** (uric acid, Vit C), <br>- **Bilirubin**, <br>- **Turbidity**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <mark class="red">TRIGLYCERIDES</mark>     | ![[Pasted image 20240423165535.png]]<br><br><mark class="red">12 - 16 hours fasting</mark><br>- 2 - 4 hrs after food intake (peak lipemia)<br>- 10 - 12 hrs (chylomicrons are cleared)<br><br>**Glycerol free tube** - collection of triglycerides<br><br>Measurement of Glycerol (basis of triglyceride measurement)<br>1. **NADH** consumption (↓ absorbance) or formation (↑ absorbance) at 340 nm<br>2. Formation of **formazan compound** (colorimetry)<br>3. Formation of **fluorescent compound**                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <mark class="red">HDL</mark> CHOLESTEROL   | <mark class="red">**Analytic Ultracentrifugation**</mark><br>- **Classic** Method <br>- **Density** range of HDL (1.063 - 1.21 g/mL)<br><br><mark class="red">**Selective Precipitation**</mark> (uses HDL precipitant, ppt's nonHDL lipoprotein, supernatant used to measure HDL)<br>- **Less dense LPP are precipitated** leaving **HDL in the supernatant**. The supernatant is measured for cholesterol level.<br>- Common precipitating reagents include: (to ppt non-HDL lipoproteins, non-Apo A containing lipoproteins)<br>  1. **Heparin-manganese-chloride** - MoC<br>  2. **Dextran sulfate-magnesium chloride**<br>  3. **Sodium phosphotungstate Mg2+**<br><br><mark class="red">**Homogenous enzyme assays**</mark> (block non-HDL LPP)<br>- **LDL and VLDL are made less reactive** with cholesterol reagent while making HDL more reactive<br>- **a-cyclodextrin** (no ppt involved, LDL, VLDL no longer reactive so no longer detected) |
| <mark class="red">LDL</mark> CHOLESTEROL   | <mark class="red">**Direct Method**</mark><br>- Uses an **apolipoprotein antibody** that separates LDL from other lipid fractions then measurement is taken using total cholesterol methods.<br>- **HDL (use ==Apo A== Ab)**<br>- **VLDL (use ==Apo E== Ab)**<br><br><mark class="red">**Friedewald Equation**</mark><br>- LDL = Total Cholesterol – (HDL + TAG/5)<br>- LDL = Total Cholesterol – (HDL + TAG/2.175)<br>NOTE: Calculation NOT VALID if<br>- TAG **>400 mg/dL**<br>- **chylomicrons** are present<br>- **cholestasis**<br>- **Type III dyslipidemia**<br>                                                                                                                                                                                                                                                                                                                                                                                  |




# Classification of Lipid Disorders by Predominant Lipids (by Fredrickson classification)

| Disorder                                                                                                                                                                   | Phenotype                          | Chol | TAG    | Clinical Features                                      |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------- | ---- | ------ | ------------------------------------------------------ |
| <mark class="red">Familial **lipoprotein lipase deficiency**</mark><br><br>NOTES<br>- required to remove TAG, if lacking, TAG not remove = ↑                               | <mark class="red">I</mark>         | ↑    | ↑↑↑    | **Eruptive xanthomas**, **pancreatitis**               |
| <mark class="red">Familial **apo C-II deficiency**</mark><br><br>NOTES<br>- LPP lipase ATTACK apo C-II in chylomicron to unload TAG, no apo C-II, no attack, no unload = ↑ | <mark class="red">I or V</mark>    | ↑    | ↑↑↑    | **Pancreatitis**                                       |
| <mark class="red">Familial hyper**cholesterol**emia</mark><br><br>NOTES<br>- LDL not converted, not delivered to tissues<br>- LDL receptor defect, Apo B100 deficiency     | <mark class="red">IIa</mark>       | ↑↑↑  | N or ↑ | **Tendinous xanthomas**, **premature atherosclerosis** |
| <mark class="red">Familial **dysbetalipoprotein**emia</mark><br><br>NOTES<br>-                                                                                             | <mark class="red">III</mark>       | ↑↑↑  | ↑↑↑    | **B-VLDL** (chole > TAG)                               |
| <mark class="red">Familial **combined hyperlipid**emia</mark><br><br>NOTES<br>- **IIb** (most common dyslipidemia)                                                         | <mark class="red">IIb or IV</mark> | ↑↑   | ↑↑     | **Premature atherosclerosis**                          |
| <mark class="red">Familial hyper**triglyceride**mia</mark>                                                                                                                 | <mark class="red">IV or V</mark>   | ↑    | ↑↑↑    | **Eruptive xanthomas**, **pancreatitis**               |

^a62avg

## ATP III Cholesterol Classification (Adult Treatment Panel)

|                                            |                                                                                                                                                                                                                                                                            |
| ------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Total Cholesterol</mark> | Desirable (<<mark class="red">200</mark> mg/dL)<br>**Borderline** (<mark class="red">200 - 239</mark> mg/dL)<br>High (><mark class="red">240</mark> mg/dL)                                                                                                                 |
| <mark class="red">LDL</mark> Cholesterol   | Optimal (<mark class="red">100</mark> mg/dL)<br>Near optimal (<mark class="red">100 - 129</mark> mg/dL)<br>**Borderline** (<mark class="red">130 - 159</mark> mg/dL)<br>High (<mark class="red">160 - 189</mark> mg/dL)<br>Very high (><mark class="red">190</mark> mg/dL) |
| <mark class="red">HDL</mark> Cholesterol   | Low (<<mark class="red">40</mark> mg/dL)<br>High (><mark class="red">60</mark> mg/dL)                                                                                                                                                                                      |


## ATP III Recommended LDL Targets

| Risk Group                                                                      | Remarks                                                                                                                                                | Target LDL                          |
| ------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------ | ----------------------------------- |
| Presence of <mark class="red">coronary artery disease</mark> or CAD equivalents | CAD equivalents: <br>- **Diabetes** <br>- **Noncoronary atherosclerotic vascular disease** <br>- **Framingham risk of MI within 10 years of ==≥20%==** | <<mark class="red">100</mark> mg/dL |
| <mark class="red">2 or more</mark> major risk factors                           | Major risk factors: <br>- **Smoking** <br>- **Hypertension** <br>- **Low HDL** <br>- **Family history** of premature CAD <br>- **Age**                 | <<mark class="red">130</mark> mg/dL |
| <mark class="red">0-1</mark> major risk factors                                 | ^                                                                                                                                                      | <<mark class="red">160</mark> mg/dL |

^dr34iv

# ELECTROLYTES


|                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">SODIUM</mark>      | - **MAIN CATION IN THE ==ECF==,** representing **==90%== of all extracellular cations**<br>- It is the **main determinant of ==plasma osmolality==**<br>- Concentration in the plasma is mainly dependent on **water intake and excretion**<br><br><br>Two hormones greatly affect sodium values:<br>**<mark class="red">ALDOSTERONE</mark>** <br>- Adrenal cortex; DCT - site of action<br>- main hypernatremic hormone<br>- retain sodium, excrete potassium (↑ Aldosterone = ↑Na, ↓K )<br>- Cushing's dss/syndrome, Conn's dss<br>**<mark class="red">ATRIAL NATRIRETIC PEPTIDE</mark>**<br>- antagonist of aldosterone<br>- cardiac atria; anti-hypertensive agent<br>- promotes natriuresis (excretion of sodium) |
| <mark class="red">POTASSIUM</mark>   | - **MAIN CATION IN THE ==ICF==**; only **==2% (3.5 - 5.1 mmol/L) of its total body concentration== found in the plasma**<br>- It is the **==CHIEF COUNTERCURRENT== OF SODIUM**<br>- Most important analyte wherein **any abnormality is ==life threatening==**<br>- Renal maintenance of normal **serum potassium** is done by: **PCT (K retained)** and **DCT (==K excreted==)**<br><br>NOTES<br>**6 mmol/L** (alteration in the ECG pattern)<br>**10 mmol/L** (cardiac arrest)                                                                                                                                                                                                                                       |
| <mark class="red">CHLORIDE</mark>    | - **==MOST ABUNDANT ANION== IN THE ECF**<br>- **Maintenance of water balance, osmolality and ==ELECTRONEUTRALITY==** (works together w/ Na)<br>- **==CHIEF COUNTERION/COUNTERBALANCE== OF SODIUM.**<br>- It has a close relationship with **bicarbonate** in the maintenance of acid-base balance<br><br>CHLORIDE SHIFT<br>- CO2 from tissues are taken in by RBC, other CO2s are mixed with water forming carbonic acid<br>- Carbonic anhydrase in RBC split carbonic acid into H and Bicarb<br>- Bicarbonate is excreted from RBC, Cl is taken into RBC for electroneutrality (CHLORIDE SHIFT)                                                                                                                       |
| <mark class="red">BICARBONATE</mark> | - **==Second most abundant anion== in the ECF**<br>- Accounts for **==90% of the total CO₂== at physiologic pH** (at normal pH, Bicarbonate:Carbonic acid ratio = 20:1)<br>- Blood specimen for bicarbonate determination must be **collected<br>anaerobically**                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <mark class="red">CALCIUM</mark>     | - **==MOST ABUNDANT CATION== IN THE BODY**<br>- **1% is found in the ==ECF==**; **99% is deposited in the ==bones== and ==teeth==**<br>- **Maximally absorbed in the ==duodenum==** favored by acid pH<br>- Calcium levels in the blood is **dependent on plasma ==protein==**<br><br>3 Forms of Ca (ECF)<br>1. **50% (==Ionized/active/free==)**<br>2. **40% (==protein-bound==)** - bound to prevent loss in kidney<br>3. **10% (==bound to anions==)**                                                                                                                                                                                                                                                              |
| <mark class="red">PHOSPHATE</mark>   | - **MAIN ANION IN THE ==INTRACELLULAR COMPARTMENT==**<br>- **Main anion ==INVERSELY RELATED TO CALCIUM==**<br>- **85% in the ==bones==** and **15% in the ==ECF==**<br><br>Hydroxyapatite (Basic Calcium Phosphate) = Bone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <mark class="red">MAGNESIUM</mark>   | - **==Second most abundant== intracellular cation** and the **==fourth most abundant== in the body**<br>- Vasodilator causing **DECREASE ==UTERINE HYPERACTIVITY==** and **INCREASE ==UTERINE BLOOD FLOW==** IN **ECLAMPSIA**<br>- It is important in maintaining DNA, RNA and ribosomal structures and involved in the synthesis of carbohydrates, proteins and lipids.<br>- **==Essential cofactor== of more than 300 enzymes**<br><br><br>TAQ polymerase                                                                                                                                                                                                                                                            |

# Sodium Disorders
## HYPONATREMIA


|                                                                                       |                                                                                                                                                                                 |
| ------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **INCREASED <mark class="red">SODIUM LOSS</mark>**<br><br>DEPLETIONAL Hyponatremia    | **Hypoadrenalism**<br>**Potassium deficiency**<br>**Diuretic abuse**<br>**Ketonuria**<br>**Salt-losing nephropathy**<br>**Prolonged vomiting or diarrhea** = Secretory diarrhea |
| **INCREASED <mark class="red">WATER RETENTION</mark>**<br><br>DILUTIONAL Hyponatremia | **Renal failure**<br>**Nephrotic syndrome**<br>**Hepatic cirrhosis**<br>**Congestive heart failure**                                                                            |
| <mark class="red">WATER IMBALANCE</mark><br><br>                                      | **Excess water intake**<br>**SIADH**<br>**Pseudohyponatremia**<br>**Hyperglycemia**<br>**Mannitol** infusion                                                                    |

> [!note]
> - Diabetic Hyperosmolality
> 	- ↑ glucose, ↑ osmolality
> 	- water goes out of the cell and dilutes Na+ = Hypertonic Hyponatremia
> - Hypertonic Hyponatremia (>295 mOsm/kg)
> 	- Hyperglycemia
> 	- Mannitol infusion
> - Degree of change in sodium  ^x45wio


## PSEUDOHYPONATREMIA
- Can occur when is sodium measured using **indirect ion-selective electrodes (ISEs)** in a **patient who is ==hyperPROTEINemic== or ==hyperLIPIDemic==.**
- An **indirect ISE ==dilutes the sample== prior to analysis** and as a result of plasma/serum water displacement; the **ion levels are falsely ==decreased==.** ^244man
- **REMEDY: measure sodium using ==direct ISE== or ==direct potentiometry==**
- ↑ proteins, ↑ lipids (hypercholesterolemia, hypertriglyceridemia, not only hyperlipidemia)
- ![[Pasted image 20240425143538.png]]
	- recall that serum glucose is affected by serum/plasma osmolality
- Serum osmolality NORMAL, osmolal gap is present


##  HYPERNATREMIA


|                                                            |                                                                                                                                                          |
| ---------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Excess <mark class="red">Water Loss</mark>                 | - **Dehydration**<br>- **Diabetes insipidus** <br>- **Renal tubular disorder** <br>- **Prolonged diarrhea** = Osmotic diarrhea<br>- **Profuse sweating** |
| **<mark class="red">Decreased</mark> Water Intake**        | - **Older persons**<br>- **Infants**<br>- **Mental impairment**                                                                                          |
| **<mark class="red">Increased</mark> Intake or Retention** | - **Hyperaldosteronism**<br>- **Sodium bicarbonate** excess<br>- **Dialysis fluid** excess                                                               |


#  POTASSIUM DISORDERS 



|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| ------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">HYPOkalemia</mark>  | <mark class="red">**Gastrointestinal loss**</mark>  -urinary K is low (<30 mEq/dL)<br>  - **Vomiting and diarrhea**<br>  - **Gastric suction**<br>  - **Intestinal tumor**<br>  - **Malabsorption**<br>  - **Cancer therapy**<br>- Large doses of **laxatives**<br> <br><mark class="red">**Renal loss**</mark>  - urinary K is high (>30 mEq/dL)<br>- **Diuretics** abuse <br>- **Nephritis**<br>- **Renal tubular acidosis** <br>- **Hyperaldosteronism** <br>- **Hypomagnesemia** <br>- **Acute leukemia**<br><br> <mark class="red">**Cellular shift**</mark> <br>  - **Alkalosis**<br>  - **Insulin overdose** (↑ activity of Na/K ATPase pump = K goes in cell, ↓ K measured outside of cell)<br><br> <mark class="red">**DECREASED intake**</mark> |
| <mark class="red">HYPERkalemia</mark> | <mark class="red">**DECREASED Renal Excretion**</mark> <br>- Acute or chronic **renal failure**<br>- **Hypoaldosteronism**<br>- **Diuretics**<br><br><mark class="red">**Cellular Shift**</mark> <br>- **Acidosis**<br>- **Muscle cellular injury**<br>- **Chemotherapy**<br>- **Leukemia**<br>- **Hemolysis**<br><br><mark class="red">**INCREASED Intake**</mark> <br>- Oral or IV **potassium replacement** therapy<br><br><mark class="red">**Artifactual**</mark> <br>- Sample **hemolysis**<br>- **Thrombocytosis**<br>- **Prolonged tourniquet** use<br>- Excessive **fist clenching**<br>- **EDTA contamination**<br>                                                                                                                             |

> [!NOTE] RTA
> - ! NO SECRETION of H+ from RTE cell
> - ↑ HCO3 excreted in urine instead of blood = Alkaline urine, Acidic blood
> - K+ excreted from RTE cell instead of H+ = HYPOKALEMIA
> - ![[Pasted image 20240425145131.png]]

![[Pasted image 20240425150141.png]]
# CALCIUM - PHOSPHATE HOMEOSTASIS

|                                                                                                                                                                          | GIT                      | Kidneys                                 | Bone                                | Net effect        |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------ | --------------------------------------- | ----------------------------------- | ----------------- |
| **<mark class="red">Parathyroid hormone</mark>**<br>(PARATHORMONE)<br>- main HYPERcalemic hormone<br>- stimulated by Ca2+<br>- conditions that ↑ PTH = eventually ↑ Ca2+ | ↑ Ca2+ & PO4- absorption | ↑ Ca2+ reabsorption<br>↑ PO4- excretion | Bone Resorption                     | ↑ Ca2+ <br>↓ PO4- |
| **<mark class="red">Calcitonin</mark>**<br>(THYROCALCITONIN)<br>- main antagonist of PTH                                                                                 | ↓ Ca2+ & PO4- absorption | ↑ Ca2+ & PO4- excretion                 | Bone Absorption                     | ↓ Ca2+ <br>↓ PO4- |
| **<mark class="red">Active Vitamin D</mark>**<br>(1.,25 dihydroxycholecalciferol)                                                                                        | ↑ Ca2+ & PO4- absorption | ↑ Ca2+ & PO4- reabsorption              | Does NOT have direct effect to bone | ↑ Ca2+ <br>↑ PO4- |

^nkupwo

![[Pasted image 20240425150119.png]]
## SERUM CALCIUM AND PTH CORRELATIONS

| Possible Causes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | iCa2+                      | PTH                        |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------- | -------------------------- |
| <mark class="red">PARATHYROID adenoma/carcinoma</mark><br>- most common cause of **1° HYPERparathyroidism**<br>- 3 hypo, only 1 hypertrophy (produces PTH)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <mark class="red">↑</mark> | <mark class="red">↑</mark> |
| <mark class="red">METASTATIC carcinoma</mark> <br>**hyperthyroidism**, **MULTIPLE MYELOMA**, **SARCOIDOSIS**, **iatrogenic** causes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <mark class="red">↑</mark> | <mark class="red">N</mark> |
| <mark class="red">Parathyroid hyperplasia</mark><br>- **4-gland hyperplasia**<br><br><mark class="red">Parathyroid hyperplasia because of an **INHERITED SYNDROME**</mark><br>- **MEN (Multiple Endocrine Neoplasia)**<br>- **Isolated Familial Hyperparathyroidism** (<mark class="red">↑ PTH → ↑ Ca2+</mark>)<br><br><mark class="red">Parathyroid hyperplasia **SECONDARY TO A DISEASE**</mark> (COMMON FORM OF P HYPERPLASIA)<br>- **Chronic Vitamin D deficiency**<br>- **Chronic kidney disease**<br>- <mark class="red">↓ Ca2+ → ↑ PTH</mark><br>- PTH ↑ consistently in response to ↓ Ca2+ to normalize levels (PTH  increases when Ca2+ is low) | <mark class="red">↓</mark> | <mark class="red">↑</mark> |

^ykct11

# NONPROTEIN NITROGENOUS COMPOUNDS

| NPN                                  | REMARKS                                                        | APP. PLASMA CONC. | APP. URINE CONC. |
| ------------------------------------ | -------------------------------------------------------------- | ----------------- | ---------------- |
| <mark class="red">UREA</mark>        | **Major excretory product** of protein metabolism              | **45-50%**        | **86%**          |
| <mark class="red">AMINO ACIDS</mark> | **Building blocks** of proteins                                | 25%               | —                |
| <mark class="red">URIC ACID</mark>   | Product of **purine catabolism**                               | 10%               | 1.7%             |
| <mark class="red">CREATININE</mark>  | Formed **from creatine and creatine phosphate** in the muscles | 5%                | 4.5%             |
| <mark class="red">CREATINE</mark>    | **Precursor** of creatinine                                    | 1-2%              | —                |
| <mark class="red">AMMONIA</mark>     | Product of **amino acid catabolism**                           | 0.2%              | 2.8%             |

^7v2vx1

> [!NOTE]
> - AZOTEMIA = ↑ in blood urea
> - UREMIA = ↑ in blood urea due to renal failure

## AZOTEMIA CLASSIFICATION

|                                     |                                                                                 |                                                                                                        |
| ----------------------------------- | ------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------ |
| <mark class="red">Prerenal</mark>   | ↓ renal perfusion (↓ renal blood flow)<br>↑ urea (stress, fever, cortico ther.) | **CHF**, **dehydration**, **hemorrhage**, **shock**, **stress**, **fever**, **corticosteroid** therapy |
| <mark class="red">Renal </mark>     | ↓ GFR due to renal dss                                                          | **Renal failure**, **Glomerulonephritis**, **Tubular necrosis**                                        |
| <mark class="red">Post Renal</mark> | obstruction in urine flow                                                       | **Renal calculi**, **Tumors**, **Severe infection**                                                    |


## BUN/CREATININE RATIO
- Used as a **better indicator** of the source of BUN and creatinine ELEVATION
- Normal ratio: **10 to 20:1**

|                                                                                        |                                                                                                                                                                                                     |
| -------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">**Low** ratio</mark>                                                 | **Acute tubular necrosis**, **low protein** intake, **starvation**, **severe liver disease**, **vomiting**<br><br>BUN is decreased<br>ammonia + CO2 —(liver)→ Urea                                  |
| <mark class="red">**High** ratio with **normal** creatinine</mark>                     | **Prerenal azotemia**, **high protein** intake, **dehydration**, **increased ==protein breakdown==**, **decreased ==kidney perfusion==**, **cortisol** treatment<br><br>ONLY BUN/UREA is increasing |
| <mark class="red">**High** ratio with **increased** creatinine</mark>                  | Post renal **obstruction**, **Severe UTI**                                                                                                                                                          |
| <mark class="red">**Normal** ratio with **elevated** urea and creatinine levels</mark> | **End stage** renal disease (TRUE RENAL DISEASE), **Acute renal failure**, **acute pyelonephritis**, **nephrotic syndrome**                                                                         |

> [!NOTE]
> - NV: (BUN: 6-20 mg/dL), (Crea: 0.8 to 1.2 mg/dL)
> - ![[Pasted image 20240425152604.png]]
> - ~ in cases of Renal Dss, N BCR, ↑ BUN, Crea

# ACID-BASE BALANCE

## HENDERSON-HASSELBACH EQUATION

- This equation states the **relationship between acid and base** and relates the **==pH== of a solution to the ==dissociation properties== of the weak acid.**
- Expresses that **blood pH depends on the ==ratio of bicarbonate to pCO2==.**
- Presents that if the kidneys and lungs are properly functioning, a **==20:1 ratio== of HCO3- to H2CO3** will be maintained.
- ~ pH = 6.1 + log HCO/pCO2 x 0.03

## Acid-Base Disorders

|                                                | 1° Cause               | 1° Compensation              | Disease/Condition                                                                                   |
| ---------------------------------------------- | ---------------------- | ---------------------------- | --------------------------------------------------------------------------------------------------- |
| Metabolic <mark class="red">Acidosis</mark>    | **Bicarbonate LOSS**   | **HYPER**ventilation         | **Ketoacidosis**, **Lactic acidosis**, **Renal failure**, **Diarrhea**                              |
| Metabolic <mark class="red">Alkalosis</mark>   | **Bicarbonate EXCESS** | **HYPO**ventilation          | **Vomiting**                                                                                        |
| Respiratory <mark class="red">Acidosis</mark>  | **HYPOventilation**    | Bicarbonate **REABSORPTION** | **COPD**, **Pneumonia**, **Stroke**, **CNS disease**, **Drug overdose**, **Botulism**, **Myxedema** |
| Respiratory <mark class="red">Alkalosis</mark> | **HYPERventilation**   | Bicarbonate **EXCRETION**    | **Anxiety**, **Severe pain**, **Aspirin overdose**, **Hepatic cirrhosis**                           |

^ex8spw

## Classifying an Acid-Base Disorder

### Determine the Primary Abnormality and if Compensation is Appropriate

- 1. Check **pH**
	- If above normal range: **Alkalosis**
	- If below normal range: **Acidosis**
	- If normal, use **7.4** as basis
- 2. Check **pH** and **pCO2** if **opposite: Respiratory**
	- Check **pH** and **HCO3** if **parallel: Metabolic**
- 3. Identify expected compensation
	- If not yet present: uncompensated
	- If already present: compensated → proceed to 4
- 4. Check pH again
	- Still out of range: **partially compensated**
	- Within **normal** range: **fully compensated**

|      | Sample 1  | Sample 2  | Sample 3  | Sample 4  |
| ---- | --------- | --------- | --------- | --------- |
| pH   | 7.32      | 7.48      | 7.49      | 7.37      |
| pCO2 | 42 mmHg   | 30 mmHg   | 32 mmHg   | 33 mmHg   |
| HCO3 | 18 mmol/L | 23 mmol/L | 19 mmol/L | 17 mmol/L |


> [!NOTE] Reference Range
> <mark class="red">pH</mark> = 7.35 - 7.45
> <mark class="red">pCO2</mark> = 35 - 45 mmHg (35 - 44 mmHg)
> <mark class="red">HCO3</mark> = 22 - 26 mmol/L (23 - 29 mmol/L)

> [!NOTE] Determine if compensation is appropriate:
> - <mark class="red">Metabolic ACIDOSIS</mark>
> 	- for each **1.3** mEq ↓ in HCO3 = the pCO2 **DECREASED by 1.0** mmHg
> - <mark class="red">Metabolic ALKALOSIS</mark>
> 	- for each **0.6** mEq ↑ in HCO3 = the pCO2 **INCREASED by 1.0** mmHg
> - <mark class="red">Respiratory acidosis/alkalosis</mark>
> 	- **<mark class="red">Acute</mark>**: for each 1 mmHg change in pCO2 = **0.1** mEq change in HCO3 in the same direction
> 	- **<mark class="red">Chronic</mark>**: for each 1 mmHg change in pCO2 = **0.4** mEq change in HCO3 in the same direction

# Differentiate the Disorders

## METABOLIC ACIDOSIS: 
- categorized by **presence and absence of ==anion gap== and ==osmolal gap==**


| Osmolal Gap Calculation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Anion Gap Calculation                                                                                                                                                                                                           |
| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">**Measured Osmolality**</mark><br>- Measured using **osmometers**<br>- **Freezing point depression**<br>- ↑ osmolality = ↓ fpo<br><mark class="red">**Estimated Osmolality**</mark> = Computed Osmolality<br>- Computed based on the **main solutes** found in the plasma<br><br><mark class="red">**Osmolal Gap**</mark>  (**N = ==<10==**)<br>**OSMOLAL GAP = MO – EO**<br>- Used to **indirectly indicate** the presence of abnormally occurring osmotically active substances in the body such as **ethanol**, **ethylene glycol**, **methanol**, and **mannitol**. | - difference between the unmeasured cation and unmeasured anions<br><br>Acceptable Formula<br>AG = (Na - K) - (Cl + HCO3)<br>AG = Na - (Cl + HCO3)<br><br>**NV = ==<12==**<br>#table-column  <br>[[CC (ASCPi)#^hdb82k\|↑ or ↓]] |


|           |                                                                                                                                               |
| --------- | --------------------------------------------------------------------------------------------------------------------------------------------- |
| Increased | - **Poisoning**<br>- **Uremia**<br>- **Diabetic ketoacidosis**<br>- **Severe dehydration**<br>- **Lactic acidosis**<br>- **Instrument** error |
| Decreased | - **Hypoalbuminemia**<br>- **Severe hypercalcemia**<br>- **Multiple myeloma**                                                                 |

^hdb82k

![[Pasted image 20240425160208.png]]

## Classification of Metabolic ACIDOSIS According to Anion Gap

|                                       |                                                                                                                                                                                                    |
| ------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">INCREASED AG</mark> | - **Methanol**<br>- **Uremia**<br>- **Ketoacidosis**<br>- **Paraldehyde**<br>- **Lactic acidosis**<br>- **Ethylene glycol**<br>- **Salicylate**                                                    |
| <mark class="red">Normal AG</mark>    | - **Diarrhea**<br>- **Recovery phase DKA**<br>- **Ureterosigmoidostomy**<br>- **NH4Cl**<br>- **Carbonic anhydrase inhibitors**<br>- **Total parenteral nutrition**<br>- **Renal tubular acidosis** |


## Correlation of INCREASED Osmolal Gap With Metabolic ACIDOSIS

|                                                     |                                                                                                             |
| --------------------------------------------------- | ----------------------------------------------------------------------------------------------------------- |
| With <mark class="red">Metabolic Acidosis</mark>    | - **Methanol**<br>- **Propylene glycol**<br>- **Ethylene glycol**<br>- **Paraldehyde**<br>- **Ethanol\***   |
| <mark class="red">WITHOUT Metabolic Acidosis</mark> | - **Isopropanol**<br>- **Glycerol**<br>- **Sorbitol**<br>- **Mannitol**<br>- **Acetone**<br>- **Ethanol\*** |

^xg0fuq


## Metabolic ALKALOSIS: 
- categorized by **chloride** responsiveness or resistance

|                                                                         |                                                                                                                                                           |
| ----------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Chloride <mark class="red">Responsive</mark> (Urine Cl = **<10 mEq/L**) | - **Diuretic** therapy<br>- **Vomiting**<br>- **Nasogastric tube suction**<br>- **Villous adenoma**<br>- **Carbenicillin**<br>- **Contraction alkalosis** |
| Chloride <mark class="red">Resistant</mark> (Urine Cl = **>10 mEq/L**)  | - **Hyperaldosteronism**<br>- **Cushing syndrome**<br>- **Exogenous steroids**<br>- **Licorice**<br>- **Bartter syndrome**<br>- **Milk alkali syndrome**  |


## BLOOD GAS ANALYSIS

- Anaerobically collected **heparinized arterial blood**
- Transported on **ice water** or **ice bath**
- Analysis must be **performed ==within 20 minutes==**
- Specimen must be **==refrigerated== if not tested within 20 minutes**
- ? POSSIBLE ERRORS IN BLOOD GAS ANALYSIS
	1. Specimen exposed to **room air** (↑pO2, ↓pCO2, ↑pH)
	2. Sealed specimen left at **room temperature** (↓pO2, ↑pCO2, ↓pH)
	3. **Excess heparin** - an acid mucopolysaccharide (↓ pH)


|                          |                                                                                                                                                                                                                                       |
| ------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Directly measured in BGA | (Potentiometry)<br>**pH (Glass electrode)** , <br>**pCO2 (Glass electrode coated w/ plastic: Severinghaus electrode)** <br><br>NOTE: pCO2 is SENSITIVE to? pH changes<br><br>(Amperometry/Polarography)<br>**pO2 (Clarke electrode)** |
| Derived value            | **HCO3**                                                                                                                                                                                                                              |


# Clinical Enzymology

> [!NOTE]
> - Enzymes are NOT consumed 
> - Enzymes are measured based on their activity
> 	- change in **substrate** concentration
> 	- change in **coenzyme** concentration
> 	- change in **product** concentration


## Enzyme Kinetics




|                                      |                                                                                                                      |
| ------------------------------------ | -------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">First</mark> Order | - Enzymes > Substrate<br>- rate of reaction is dependent on SUBSTRATE concentration<br>- glucose oxidase, hexokinase |
| <mark class="red">Zero</mark> Order  | - Enzymes < Substrate<br>- rate of reaction is dependent on ENZYME concentration<br>- enzyme determination methods   |


## Enzyme Determination Assays



|                                                           |                                                                                                                                                              |
| --------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| <mark class="red">Fixed Time/ End-point/ One-point</mark> |                                                                                                                                                              |
| <mark class="red">Kinetic/ Continuous Monitoring</mark>   | - preferred<br>- measure change of absorbance reading<br>- data gathered is a result of zero order reaction<br>- eliminate lag phase or substrate exhaustion |

## MAJOR ENZYMES OF CLINICAL SIGNIFICANCE


| Enzyme                                              | Clinical Significance                                                     |
| --------------------------------------------------- | ------------------------------------------------------------------------- |
| <mark class="red">Acid phosphatase</mark>           | **Prostatic carcinoma**                                                   |
| <mark class="red">Alkaline phosphatase</mark>       | Hepatic disorder, **Bone disorder**                                       |
| <mark class="red">Gamma glutamyltransferase</mark>  | Hepatic disorder                                                          |
| <mark class="red">Alanine aminotransferase</mark>   | Hepatic disorder                                                          |
| <mark class="red">Aspartate aminotransferase</mark> | **Myocardial infarction**, Hepatic disorder, **Skeletal muscle disorder** |
| <mark class="red">Aldolase</mark>                   | **Skeletal muscle disorder**                                              |
| <mark class="red">Creatine kinase</mark>            | **Myocardial infarction**, **Skeletal muscle**                            |
| <mark class="red">Lactate dehydrogenase</mark>      | **Myocardial infarction**, Hepatic disorder, **Hemolysis**, **Carcinoma** |
| <mark class="red">Amylase</mark>                    | **Acute pancreatitis**                                                    |
| <mark class="red">Lipase</mark>                     | **Acute pancreatitis**                                                    |
| <mark class="red">Chymotrypsin</mark>               | **Chronic pancreatitis deficiency**                                       |
| <mark class="red">Elastase-1</mark>                 | **Chronic pancreatitis deficiency**                                       |
| <mark class="red">Pseudocholinesterase</mark>       | **Hepatic disorder**, **organophosphate poisoning**                       |

## LACTATE DEHYDROGENASE
- Considered as the **least specific enzyme**
- **LDH is ==cold labile==**, should not be stored in the refrigerator
	- store in refrigerator
- $ Major isoenzymes: (desc. order of abundance)
	- **LD2** (Heart & RBCs; 29-31%)
	- **LD1** (Heart & RBCs; 14 - 26%)
		- most anodal
	- **LD3** (Intestines, Lungs, Pancreas; 20 - 26%)
		- used as tumor marker for pulmonary-involving carcinoma
	- **LD4** (Liver, Skeletal muscles; 8 - 16%)
	- **LD5** (Liver, Skeletal muscles; 6-16%)
		- used to asses Liver function
- ~ **LD6**: <mark class="red">Alcohol dehydrogenase</mark>
	- present in **arteriosclerotic cardiovascular failure**
	- seen together with LD5 ↑
- LD-Flipped Pattern: **LD1 > LD2**
	- **Hemolytic anemia**
	- **Myocardial infarction**
	- **Renal infarction**
- ! Highest elevation is often seen in <mark class="red">MEGALOBLASTIC ANEMIA (PERNICIOUS)</mark>

## ALKALINE PHOSPHATASE
- Often used in evaluation of **hepatobiliary and bone disorders**
- ! Highest elevation is seen in <mark class="red">PAGET'S DSS/ OSTITIS DEFORMANS</mark>
- Physiologic elevation can be seen in Pregnancy, Bone growth (children)
- Increased after having a high-fat meal (intestinal ALP ↑)
- Bone > Liver > Intestinal > Placental

### DIFFERENTIATION OF MAJOR ALP ISOENZYMES

| Isoenzymes | Electrophoresis (anode to cathode) | Heat denaturation (stable to labile) | Chemical inhibition (↓ isoenzymes) |
| ---------- | ---------------------------------- | ------------------------------------ | ---------------------------------- |
| BONE       | 2                                  | 4                                    | **levamisole**, **urea**           |
| LIVER      | 1                                  | 3                                    | **levamisole**                     |
| INTESTINAL | 4                                  | 2                                    | **L-phenylalanine**                |
| PLACENTAL  | 3                                  | 1                                    | **L-phenylalanine**                |

^7rnknw

> [!NOTE]
> - Enzyme that best correlates with ALP = GGT
> 	- GGT ↑ (Liver disease)
> 	- GGT N (BoNe disease)

### METHODS OF MEASURING TOTAL ALP ACTIVITY


| METHOD                                              | SUBSTRATE USED          | REMARKS                                                                        |
| --------------------------------------------------- | ----------------------- | ------------------------------------------------------------------------------ |
| <mark class="red">Shinowara, Jones, Reinhart</mark> | beta-glycerophosphate   | - **Long incubation time**<br>- **High blank values**<br>- **Endpoint method** |
| <mark class="red">King and Armstrong</mark>         | phenylphosphate         | - Requires **protein removal**                                                 |
| <mark class="red">Bessy, Lowry, Brock</mark>        | p-nitrophenyl phosphate | - **Endpoint or kinetic**<br>- **Rapid technique**                             |
| <mark class="red">Bowers and McComb</mark>          | p-nitrophenyl phosphate | - **Reference** method<br>- Uses **phosphate-accepting buffer**                |

^1x8zsk

## ASPARTATE AMINOTRANSFERASE
- Often used **in conjunction with ==ALT==** for **liver** assessment
- A **cardiac marker**
- Requires **==pyridoxal phosphate (v B6)== as coenzyme**
- ? Highly affected by **hemolysis**

## ALANINE AMINOTRANSFERASE
- **Most liver specific** aminotransferase
- Relatively **NOT AFFECTED by hemolysis**
- ! HIGHEST elevation is found in <mark class="red">ACUTE VIRAL HEPATITIS</mark>

> [!NOTE]
> ALP & GGT (for assessment of HepatoBILLIARY disease)
> AST & ALT (for assessment of HepatoCELLULAR disease)

> [!NOTE] De Ritis Ratio (AST:ALT)
> - **NV: <<mark class="red">1.0</mark>**
> - Low: <mark class="red">Viral hepatitis</mark>
> - \>1.0 but <2.0: <mark class="red">Cirrhosis</mark>
> - \> 2.0:<mark class="red"> Alcoholic hepatitis; hepatocellular carcinoma</mark>

## AMYLASE
- Catalyzes **breakdown of starch and glycogen** into smaller sugars
- **Smallest enzyme normally filtered** or cleared from the circulation immediately
- $ Two isoenzymes
	- **Salivary amylase (==Ptyalin==)**
	- **Pancreatic amylase (==Amylopsin==)**
- MUMPS (↑ amylase, N lipase); Parotitis
- inhibited by LIPIDS (↓ Amylase)

## LIPASE
- Hydrolyzes the **ester linkages of fats** to produce alcohol and fatty acids
- **Most specific marker for ==acute pancreatitis==**
	- **Chronic Pancreatitis (==↓ AMS & LPS==)** = depletion of organ source
- **==Hemolysis== decreases lipase activity** while presence of **==bacteria== increases it**

# BILIRUBIN
## BILIRUBIN ASSAYS


> [!NOTE] Van der Berg Reaction
> (1st Rx) Bilirubin + Diazo reagent → Azobilirubin (measured is B2)
> (2nd Rx) Bilirubin + Accelerator → Azobilirubin (measures T. Biluribin, B1 is measured already due to accelerator; B1 = T. Bil - B2)

|                               | <mark class="red">EVELYN-MALLOY</mark><br><br>(serum only = less protein) | <mark class="red">JENDRASSIK-GROF</mark><br><br>(candidate as reference method; increased sensitivity; not affected by high protein levels )<br>(serum or plasma = not affected) |
| ----------------------------- | ------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| pH                            | **Acid**                                                                  | **Alkaline**                                                                                                                                                                     |
| Dissociating agent            | **50% methanol**                                                          | **Caffeine Sodium Benzoate**                                                                                                                                                     |
| Diazo product                 | **Red**                                                                   | **Blue**                                                                                                                                                                         |
| Wavelength used #table-column | **560 nm**                                                                | **600 nm**                                                                                                                                                                       |

^fntfw5


## BILIRUBIN METABOLISM




|                                                                                   |                                                                                                                 |
| --------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------- |
| <mark class="red">B1</mark>                                                       | - **unconjugated** bilirubin<br>- water **insoluble**<br>- **indirect** <br>- **prehepatic**<br>- **non-polar** |
| <mark class="red">B2</mark> (conjugated bilirubin) - B1 conjugated to be excreted | - water **soluble**<br>- **direct**<br>- **post hepatic** <br>- **polar**<br>- **bilirubin diglucoronide**      |

- ~ (<mark class="red">B1 + glucoronic acid → B2</mark>) facilitated by **UDPGT** (uridyl diphosphate glucorosyl transferase)
- ! **JAUNDICE**
	- common manifestation of bilirubin derangement

![[Pasted image 20240425083524.png]]

## DERRANGEMENTS IN BILIRUBIN METABOLISM




|                                                                                                                                                                                          |                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">**PREHEPATIC**</mark><br><br>- problems existing in the BLOOD<br><br>(↑B1, B2, **↑ urobilinogen**, — urine bilirubin)                                                  | **Hemolytic anemia**, **Hemolytic disease of the newborn**                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <mark class="red">**HEPATIC**</mark>                                                                                                                                                     | **Unconjugated**<br><br>↑ B1                                                                                                                                                                                | 1. **<mark class="red">Gilbert's Syndrome</mark>**: **Transport defect** with UDPGT deficiency<br>- **Defective hepatic uptak**e of bilirubin<br>- most common cause of hereditary ↑ bilirubin<br><br>2. **<mark class="red">Crigler-Najjar Syndrome</mark>**: **Conjugation defect** due to UDPGT deficiency<br>   - **<mark class="red">Type I</mark>**: **absolute** UDPGT deficiency (>20.7 mg/dL)<br>   - **<mark class="red">Type II</mark>**: **partial** UDPGT deficiency (brain damage)<br><br>3. **<mark class="red">Lucey-Driscoll Syndrome</mark>**: Presence of **antibodies** against UDPGT |
| ^                                                                                                                                                                                        | **Combined**<br><br>↑B1, ↑B2, **↑urobilinogen**, + urine bilirubin                                                                                                                                          | **Viral hepatitis**, **Cirrhosis**, **Hepatic carcinoma**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ^                                                                                                                                                                                        | **Conjugated**<br><br>↑B2                                                                                                                                                                                   | 1. **<mark class="red">Dubin-Johnson syndrome</mark>**: **Impaired transport** of conjugated bilirubin into the canaliculi<br>   - Defect in **ATP binding cassette/CMOAT system**<br>   - Abnormal gall bladder function; Presence of **dark pigmentation** in the liver<br><br>2. **<mark class="red">Rotor Syndrome</mark>**: Reduction in the concentration or activity of **ligandin** (transport of bilirubin inside the liver)<br>   - Normal gall bladder function; **Absence of dark pigmentation** in the liver<br>- **viral** origin, **nonitching jaundice**                                  |
| <mark class="red">**POST HEPATIC**</mark><br><br>↑B2, ↑B1, **↓urobilinogen**, + urine bilirubin<br><br>(B1 also increased because carried back upstream by B2)<br><br>CLAY-COLORED stool | **Biliary obstruction**, **Pancreatic cancer**, **Cholestasis**, **choledocholithiasis**<br><br>NOTES<br>- bile duct and pancreatic duct are beside each other; if pancreas enlarges, bile duct is squished |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

^0qhk15



# CARDIAC FUNCTION ASSESSMENT

- ! <mark class="red">ACUTE MYOCARDIAL INFARCTION </mark> 
	- Results from an **abrupt reduction in blood flow to a region of myocardial tissue,** usually caused by **atherosclerosis** of the coronary arteries



| CARDIAC MARKERS <br>(MiCAL)                                                     | Onset of Elevation | Peak Activity | Duration of Elevation | REMARKS                                                                             |
| ------------------------------------------------------------------------------- | ------------------ | ------------- | --------------------- | ----------------------------------------------------------------------------------- |
| <mark class="red">Myoglobin</mark><br><br>Structural Protein                    | 1 - 3 hours        | 5 - 12 hours  | 18 - 30 hours         | Earliest, NONSPECIFIC cardiac marker                                                |
| <mark class="red">Troponin I</mark><br><br>Structural Protein                   | 3 - 6 hours        | 12 - 18 hours | 5 - 10 days           | GOLD STANDARD                                                                       |
| <mark class="red">CK</mark><br><br>Enzyme<br>cornerstone of post-MI management  | 6 - 8 hours        | 24 hours      | 3 - 4 days            | CK-MB (4-8 hours → 12-24 hours → 2-3 days)<br><br>Earliest ENZYMATIC cardiac marker |
| <mark class="red">AST</mark><br><br>Enzyme<br>cornerstone of post-MI management | 6 - 8 hours        | 24 hours      | 5 days                |                                                                                     |
| <mark class="red">LDH</mark><br><br>Enzyme<br>cornerstone of post-MI management | 12 - 24 hours      | 48 - 72 hours | 10 days               |                                                                                     |

^ehczvp

# THYROID FUNCTION ASSESSMENT

## THYROID HORMONE SYNTHESIS


|                                             |                                                                                                                    |
| ------------------------------------------- | ------------------------------------------------------------------------------------------------------------------ |
| 1. <mark class="red">Iodide trapping</mark> | **uptake** of iodide                                                                                               |
| 2. <mark class="red">Oxidation</mark>       | Iodide is **converted to ==iodine==**                                                                              |
| 3. <mark class="red">Organification</mark>  | **Incorporation of iodine with tyrosine** residues of thyroglobulin                                                |
| 4. <mark class="red">Coupling</mark>        | Combination of **MIT (Monoiodothyronine)** and **DIT (Diiodothyronine)**<br><br>1 MIT + 1 DIT = 1T3<br>2 DIT = 1T4 |
| 5. <mark class="red">Release</mark>         | Release into the circulation through the **action of proteases**                                                   |


## THYROID HORMONES


|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                              |
| ----------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| T4/<mark class="red">THYROXINE</mark> / <mark class="red">TETRAIODOTHYRONINE</mark> | - **Main hormone** released from the thyroid gland<br>- **Most abundant** thyroid hormone<br>- Distribution: **70% is ==TBG==**, **20% ==TBPA==**, **10% ==TBA==**                                                                                                                                                                                                           |
| T3/<mark class="red">TRIIODOTHYRONINE</mark>                                        | - **Peripheral tissues have ==higher binding affinity for T3==** than to T4<br>- **Most active** thyroid hormone<br>- **Less tightly bound** to serum proteins; no affinity to TBPA (unlike T4, only TBG, TBA)<br>- **Majority comes from ==peripheral deiodinization of T4==** (alpha portion T4 → becomes T3 (active form); beta portion T4 → becomes rT3 (inactive form)) |


## Selected Thyroid Conditions

> [!NOTE]
> REMEMBER: ↑ Thyroid hormone = ↓ Lipids (INVERSLY PROPORTIONAL)



|                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                    |
| ------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| <mark class="red">HASHIMOTO’S THYROIDITIS</mark> | - Associated with the presence of <mark class="red">**anti-microsomal Ab**, **anti-TPO** (main), **anti-thyroglobulin**</mark><br>- **Cold intolerance**, **weight gain**, **decreased ==basal metabolic rate== and ==sympathetic response==**<br><br>- 1° HYPOthyroidism                                                                                                                                          |
| <mark class="red">GRAVES DISEASE</mark>          | - Associated with the presence of <mark class="red">**anti-TSH receptor Ab** (main), **anti-TPO**, **anti-thyroglobulin**</mark><br>- **Heat intolerance**, **weight loss**, **increased ==basal metabolic rate== and ==sympathetic response==**<br><br>- 1° HYPERthyroidism (EXOPHTHALMIA)<br><br>NOTES other names<br>Anti-TSH receptor Ab<br>Thyroid-stimulating immunoglobulin (TSI)<br>Long-acting TSH (LATS) |
| <mark class="red">EUTHYROID SICK SYNDROME</mark> | - Characterized by **normal thyroid** but **unusually low T3 and T4**; Often found in **critically-ill**, hospitalized patients<br>- Characteristic laboratory finding is increased level of **<mark class="red">↑ rT3</mark>**                                                                                                                                                                                    |
| <mark class="red">SUBCLINICAL</mark>             | - Subclinical **hypo**thyroidism: <mark class="red">**N T3, T4**, **↑ TSH**</mark><br>- Subclinical **hyper**thyroidism: <mark class="red">**N T3, T4**; **↓ TSH**</mark>                                                                                                                                                                                                                                          |



# ADRENAL FUNCTION ASSESSMENT

## Hormones Produced by the Adrenal CORTEX



> [!NOTE]
> Only cortisol stimulates the hypothalamus for hormone production
> Aldosterone is responded by RAAS
> ![[Pasted image 20240425193009.png]]



|                                      |                                                                                                                                                                       |
| ------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">Aldosterone</mark> | - Promote **sodium and water reabsorption** by the kidney to help maintain blood pressure and tonicity<br>- Regulated by the **renin-angiotensin-aldosterone system** |
| <mark class="red">Cortisol</mark>    | - Exhibits **diurnal** variation; Regulated by ACTH production through the **HPA (Hypothalamus-Pituitary-Adrenal Gland) axis**<br>                                    |
| <mark class="red">Androgens</mark>   | - **Androgens**, **estrogens**; Involved in the development of **2° sexual characteristics**<br>                                                                      |


> [!Take Note]
> **Plasma cortisol** values normally display diurnal variation, with the **highest levels occurring in the ==morning==** and the **lowest levels in the ==early evening==**. Evening values are <50% of the early morning concentrations. Classically, samples are drawn at 8 a.m. and 4 p.m. Cortisol production is **regulated by ==ACTH==**. ACTH is secreted in a pulsatile fashion by the pituitary gland. Diurnal variation causes ACTH and cortisol levels to be **highest in the ==early morning== (8 AM)** and **lowest at ==night== (10 PM to 12 AM).**

## Hormones Produced by the Adrenal MEDULLA



|                                                        |                                                                                                                                                                                                                                                               |
| ------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">NOREPINEPHRINE/ NORADRENALINE</mark> | - Produced by the **sympathetic ganglia**; Highest concentration in the **CNS**<br>- Acts as **neurotransmitter in both CNS and SNS**<br>- Metabolites: <mark class="red">**MHPG (3-methoxy-4-hydroxyphenylglycol)**; **VMA (Vanillyl Mandelic Acid)**</mark> |
| <mark class="red">EPINEPHRINE/ ADRENALINE</mark>       | - Produced **from norepinephrine**; Comes only from the **adrenals**<br>- Metabolites: <mark class="red">**VMA** (Major); **Metanephrines**, **Normetanephrines**, **HVA (Homovanillic acid)**</mark>                                                         |
| <mark class="red">DOPAMINE</mark>                      | - Produced from the **decarboxylation of ==3,4-dihydroxyphenylalanine==**<br>- Highest concentration in the **brain**<br>- Metabolites: **<mark class="red">HVA (Major)</mark>**<br><br>- Only catecholamine that can be found **INTACT in the URINE**        |


## SELECTED ADRENAL GLAND CONDITIONS


|                                                                   |                                                                                                                                                                                                                                                                                                                                                            |
| ----------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">CUSHING’S SYNDROME</mark><br><br>↑cortisol      | - Group of clinical and metabolic disorders characterized by **adrenocortical hyperfunction**<br>- Clinical Findings: **Hirsutism**, **obesity**, hypertension, **buffalo hump**, **moon-shaped face**<br><br>![[CC (ASCPi)#^lkeuzg]]                                                                                                                      |
| <mark class="red">ADDISON’S DISEASE</mark><br><br>HYPOadrenalism  | - **Decreased ==aldosterone==, ==cortisol== and other steroids**<br>- Can be due to **defect in ==hypothalamus==, ==pituitary== or ==adrenal gland==**                                                                                                                                                                                                     |
| <mark class="red">CONN’S DISEASE</mark><br><br>only aldosterone ↑ | - **Aldosterone-secreting adrenal adenoma**<br>- **Primary aldosteronism**                                                                                                                                                                                                                                                                                 |
| <mark class="red">PHEOCHROMOCYTOMA</mark><br><br>30-50 yo         | - Tumor of the **adrenal medulla** or **sympathetic ganglia** resulting to **overproduction of catecholamines** (REMEMBER: catecholamines are hyperglycemic hormones = **HYPERGLYCEMIA**)<br>- Symptoms: hypertension, tachycardia, headache, sweating and tightness of chest<br>- Diagnostic test: **<mark class="red">24-hr urine metanephrines</mark>** |
| <mark class="red">NEUROBLASTOMA</mark><br><br>CHILDREN            | - **Fatal malignant condition in ==children==** results to **excessive norepinephrine production**<br>- Elevated urinary excretion of **HVA** or **VMA** or both, and **<mark class="red">dopamine</mark>**<br>- Diagnostic test: **<mark class="red">Serum or Urine Catecholamines</mark>**                                                               |


|                                                                                 |                  |
| ------------------------------------------------------------------------------- | ---------------- |
| **<mark class="red">Pituitary Cushing's</mark>**<br><br>2°<br>Cushing's disease | ↑ACTH, ↑cortisol |
| **<mark class="red">Adrenal Cushing's</mark>**<br><br>1°                        | ↓ACTH, ↑cortisol |

^lkeuzg

# THERAPEUTIC DRUG MONITORING

## KEY PROCESSES INVOLVED IN DRUG DISPOSITION


| LADME                                 |                                                                                                                                  |
| ------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">LIBERATION</mark>   | - **Release** of the drug<br>                                                                                                    |
| <mark class="red">ABSORPTION</mark>   | - Rate at which the drug **leaves the administration site**<br>- Transport of the drug from the administration site to the blood |
| <mark class="red">DISTRIBUTION</mark> | - Refers to the **equilibrium of drug** with body tissue and plasma protein<br>- Refers to the **delivery of drug tissues**      |
| <mark class="red">METABOLISM</mark>   | - Process of **chemical modification of drug** by cells<br>- Usually occurring in the **liver** aka **BIOTRANSFORMATION**        |
| <mark class="red">EXCRETION</mark>    | - Drugs and its **metabolites are excreted** from the body<br>- Primarily occurs in the **liver**                                |

> [!NOTE] FIRST-PASS metabolism
> route undergone by ORALLY ADMINISTERED drugs; ↓ bioavailability

## PEAK, TROUGH LEVELS




|                                        |                                                                                                                                                                                                                                                                                                                                                                                 |
| -------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">PEAK</mark> LEVELS   | - Screens for **drug toxicity**<br>- Specimens are collected when the **highest serum concentration of the drug is anticipated.**<br>	- **Intravenous** administration (**30 mins**)<br>	- **Intramuscular** administration (**45 mins**)<br>	- **Oral** administration (**1-2 hours**)<br><br>usually 1 **hour after the dosage** - specimen collected to check for peak level |
| <mark class="red">TROUGH</mark> LEVELS | - Monitored to ensure that levels of the drug **stay within therapeutic range**<br>- Specimens are **collected when the lowest serum concentration of the drug is expected** which is usually immediately **==prior== to administration od the next** scheduled dose<br><br>**right before the next dose** - specimen collected                                                 |



> [!NOTE]
> For a drug to be **beneficial**, the **==PEAK level== must not exceed the toxic level** and the **==TROUGH level== must remain within the therapeutic range**.
> ![[Pasted image 20240425194732.png]]

> [!NOTE]
> - **<mark class="red">HALF-LIFE</mark>**: Time required to **reduce a drug level to half** of its initial value
> 	- usually the **BASIS of dosage**
> - **<mark class="red">STEADY STATE</mark>**: Time during which the concentration of the drug in the body stays **consistent**.
> 	- achieved usually **after 4 - 7 doses** 
> 	- (example: half life of drug is 2 hours, steady state is achieved at 8 - 14 hours)



## Therapeutic Drugs


|                                            |                                                                                                                                                                                                                                                                                                                                  |
| ------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <mark class="red">CARDIOTROPICS</mark>     | - Commonly used to treat **cardiac arrhythmias** and **congestive heart failure**<br>- Examples: <mark class="red">**Digoxin**, **Digitoxin**, **Procainamide (metabolite: N-acetylprocainamide)**, **Lidocaine**, **Quinidine**, **Propanolol**, **Disopyramide**</mark>                                                        |
| <mark class="red">ANTICONVULSANTS</mark>   | - Used in treatment of **seizure** disorders, in particular **grand mal**, **petit mal** and **psychomotor seizures** and other generalized seizure disorders<br>- Examples: <mark class="red">**Phenobarbital**, **Phenytoin**, **Primidone (m: phenobarbital)**, **Ethosuximide**, **Carbamazepine**, **Valproic acid**</mark> |
| <mark class="red">ANTIASTHMATICS</mark>    | - Bronchodilators for treatment of **moderate to severe asthma**, both for the prevention of attacks and for treatment of **symptomatic exacerbations**<br>- Example: <mark class="red">**Theophylline**</mark>                                                                                                                  |
| <mark class="red">ANTIINFLAMMATORY</mark>  | - **Analgesics**, prevents prostaglandin synthesis<br>- Examples: <mark class="red">**Acetaminophen** (hepatotoxic, responsible for coma; AST/ALT used to evaluate the toxic effect), **Acetylsalicylic acid**, **Ibuprofen**</mark>                                                                                             |
| <mark class="red">IMMUNOSUPPRESIVES</mark> | - Utilized in the **prevention of ==GVHD==**<br>- Examples: <mark class="red">**Cyclosporine**, **Tacrolimus**, **Rapamycin**</mark>                                                                                                                                                                                             |
| <mark class="red">ANTINEOPLASTIC</mark>    | - **Chemotherapeutic drugs**<br>- <mark class="red">**Methotrexate**</mark>                                                                                                                                                                                                                                                      |
| <mark class="red">ANTIDEPRESSANTS</mark>   | - Used in the treatment of **psychiatric affective disorders**<br>- Examples: <mark class="red">**TCAD**, **Lithium**</mark>                                                                                                                                                                                                     |

